Lead Sponsor

IRCCS San Raffaele

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•age of at least 18 years with diagnosis of RCC;
•patients candidates to radical nephrectomy and extended lymphadenectomy
•clinical T4 cancers or renal masses with evidence of lymphadenopathies at preoperative CT scan or larger tumor (max diameter\>10 cm)
•performance status 0-1;
•expected survival time of at least 3 months;
•recovery from toxic effects of any previous treatment;
•serum biochemical and haematological measurements within healthy parameters.
•Female patients of childbearing age were requested to have a negative pregnancy test
•ability to understand and understand informed consent
•acceptance and signature of informed consent

•other medical conditions that might limit the amount of antibody to be administered;
•New York Heart Association Class III/IV cardiac disease;
•pregnancy and breastfeeding
•eGFR\<30;
•women of child-bearing age who do not agree to use contraceptives to avoid pregnancy;
•history of autoimmune hepatitis;
•allergy to iodine;
•unavailability or immunological and clinical follow-up assessments;
•participation in another clinical trial involving an investigational agent within 4 weeks of study enrolment

Related studies

NCT06661720 · Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), and more

NCT07117227 · Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), and more

NCT05176483 · Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), and more

NCT07369505 · Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), and more

NCT07175480 · Renal Cell Carcinoma (RCC), Metastatic Renal Cell Carcinoma (mRCC)

FAZA PET IMAGING IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS